Canagliflozin vs Durvalumab

## Canagliflozin vs Durvalumab: Overview

This comparison examines the pharmacological differences between **Canagliflozin** and **Durvalumab**.

## Mechanism of Action

**Canagliflozin**: Selective SGLT2 inhibitor reducing renal glucose reabsorption and lowering blood glucose.

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Canagliflozin — 10.6 hours; Durvalumab — 17 days.

## Chemical Properties

**Molecular Formula**: Canagliflozin — C24H25FO5S; Durvalumab — N/A.

**Molecular Weight**: Canagliflozin — 444.5170 g/mol; Durvalumab — N/A.

**Type**: Canagliflozin — Small molecule; Durvalumab — Antibody.